^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Foresight CLARITY™

    Company:
    Foresight Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    Foresight CLARITY is an ultra-sensitive, liquid-biopsy platform that detects minimal residual disease (MRD) across multiple indications using proprietary PhasED-Seq™ circulating tumor DNA (ctDNA) technology.
    Cancer:
    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma
    Method:
    Liquid biopsy